Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (Q36267666)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (English)

1 reference

Europe PubMed Central

13 August 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

27

1 reference

Europe PubMed Central

13 August 2017

object named as

Elaine S Jaffe

29

0 references

object named as

Elias Campo

24

0 references

Randy D Gascoyne

31

object named as

Randy D Gascoyne

1 reference

Europe PubMed Central

13 August 2017

11

object named as

Wing C Chan

1 reference

Europe PubMed Central

13 August 2017

Dennis D Weisenburger

23

object named as

Dennis D Weisenburger

1 reference

Europe PubMed Central

13 August 2017

Joseph M Connors

4

object named as

Joseph M Connors

1 reference

Europe PubMed Central

13 August 2017

Andreas Rosenwald

25

object named as

Andreas Rosenwald

1 reference

Europe PubMed Central

13 August 2017

16

object named as

Lisa M Rimsza

1 reference

Europe PubMed Central

13 August 2017

Rita M. Braziel

20

object named as

Rita M Braziel

1 reference

Europe PubMed Central

13 August 2017

3

object named as

Kerry J Savage

1 reference

Europe PubMed Central

13 August 2017

12

object named as

Javeed Iqbal

1 reference

Europe PubMed Central

13 August 2017

10

object named as

Laurie H Sehn

1 reference

Europe PubMed Central

13 August 2017

Christian Steidl

9

object named as

Christian Steidl

1 reference

Europe PubMed Central

13 August 2017

2

object named as

Graham W Slack

1 reference

Europe PubMed Central

13 August 2017

Susana Ben-Neriah

5

object named as

Susana Ben-Neriah

1 reference

Europe PubMed Central

13 August 2017

6

object named as

Sanja Rogic

1 reference

Europe PubMed Central

13 August 2017

Patrick Brunhoeber

18

object named as

Patrick Brunhoeber

1 reference

Europe PubMed Central

13 August 2017

author name string

Nathalie A Johnson

1

1 reference

Europe PubMed Central

13 August 2017

David W Scott

7

1 reference

Europe PubMed Central

13 August 2017

King L Tan

8

1 reference

Europe PubMed Central

13 August 2017

Paul N Meyer

13

1 reference

Europe PubMed Central

13 August 2017

Georg Lenz

14

1 reference

Europe PubMed Central

13 August 2017

George Wright

15

1 reference

Europe PubMed Central

13 August 2017

Carlo Valentino

17

1 reference

Europe PubMed Central

13 August 2017

Thomas M Grogan

19

1 reference

Europe PubMed Central

13 August 2017

James R Cook

21

1 reference

Europe PubMed Central

13 August 2017

Raymond R Tubbs

22

1 reference

Europe PubMed Central

13 August 2017

German Ott

26

1 reference

Europe PubMed Central

13 August 2017

Christina Holcroft

28

1 reference

Europe PubMed Central

13 August 2017

Louis M Staudt

30

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

30 July 2012

1 reference

Europe PubMed Central

13 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

13 August 2017

30

1 reference

Europe PubMed Central

13 August 2017

3452-3459

1 reference

Europe PubMed Central

13 August 2017

28

1 reference

Europe PubMed Central

13 August 2017

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Malignant pirates of the immune system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Double-hit B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Aggressive lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

MYC as a regulator of ribosome biogenesis and protein synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Apoptotic signaling by c-MYC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Widespread microRNA repression by Myc contributes to tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

The c-myc promoter: still MysterY and challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

BCL2 translocation frequency rises with age in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

30 September 2017

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

29 June 2018

High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

Myc increases self-renewal in neural progenitor cells through Miz-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

Molecular diagnosis of Burkitt's lymphoma

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

5 December 2018

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3454768

22 September 2018

c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability

1 reference

https://pubmed.ncbi.nlm.nih.gov/22851565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22851565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization

1 reference

https://pubmed.ncbi.nlm.nih.gov/22851565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution

1 reference

https://pubmed.ncbi.nlm.nih.gov/22851565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22851565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/22851565

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.41.0985

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36267666&oldid=1858063282"